Business
Case Western Collaboration
Case Western Collaboration.
About this update from Nanoco Group Plc
[{"type":"text","content":"\n Evolutec Group PLC\n24 May 2006\n\n\nFor immediate release 24 May 2006\n\n\n\n EVOLUTEC GROUP PLC\n\n ('Evolutec' or 'the Company')\n\n\n\n CASE WESTERN RESERVE UNIVERSITY TO COLLABORATE\n\n IN MYASTHENIA GRAVIS\n\n\n\nEvolutec Group plc (AIM: EVC), the biopharmaceutical company developing novel\nproducts for the treatment of allergic, inflammatory and autoimmune diseases, is\npleased to announce that Case Western Reserve University, Cleveland, Ohio, ('\nCase') is to carry out further preclinical studies of rEV576, Evolutec's second\ndevelopment candidate, in the auto-immune disease myasthenia gravis. Evolutec\nwill provide the rEV576 and Case will provide the research funding.\n\n\n\nThe preclinical programme, which will consider the effectiveness of rEV576 as a\npotential treatment for myasthenia gravis, will be undertaken during 2006 by\nProfessor Henry J. Kaminski, Case's Vice Chair of Neurology.\n\n\n\nProfessor Kaminski's interest follows the striking positive preclinical result\nin myasthenia gravis announced by Evolutec in September 2005, in which a single\ndose of rEV576 completely prevented paralysis and weight loss over a five day\nperiod.\n\n\n\nMyasthenia gravis, of which there are approximately 36,000 cases in the US,\nresults in progressive fatigue, loss of muscle tone and in severe cases\nincreasing paralysis. There is no existing curative therapy for the condition,\nand Evolutec has applied for Orphan Drug Status from the US Food and Drug\nAdministration.\n\n\n\nMark Carnegie Brown, Evolutec's Chief Executive Officer, commented: 'We are\ndelighted by Professor Kaminski's interest in rEV576. Pending a successful\noutcome of this collaboration and other preclinical programmes, we aim to\nprogress rEV576 to the clinic in 2007.'\n\n\n\nProfessor Henry J. Kaminski commented: 'I am excited about rEV576 as it appears\nto have the qualities required to treat this debilitating and progressive\nautoimmune disease. I look forward to the results from this programme.'\n\n\n\n ENDS\n\n\nFor further information:\nEvolutec 0118 922 4480\nMark Carnegie Brown, Chief Executive Officer\nNicholas Badman, Chief Financial Officer\nwww.evolutec.co.uk\n\nBuchanan Communications 020 7466 5000\nMark Court/Tim Anderson/Mary-Jane Johnson\n\nNotes for Editors:\n\nAbout Evolutec\n\nEvolutec, which is based in Reading, UK, is a clinical sta...